Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorBeijing Hospital
About this trial
The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.
Eligibility criteria
Qualifiers
Age 18 to 70 years (inclusive) at enrollment, regardless of gender.
Voluntary signing of the informed consent form.
Newly diagnosed type 2 diabetes mellitus patients, diagnosed according to the WHO 1999 criteria, with a disease duration ≤1 year.
HbA1c between 7.5% and 10.0%.
Disqualifiers
Patients with type 1 diabetes or other types of diabetes.
History of obstructive intestinal diseases or potential complications: subjects with post-abdominal surgery or peritoneal infection-related intestinal adhesions, intestinal obstruction sequelae; subjects with intestinal motility disorders, chronic constipation; subjects with a history of Crohn's disease or ulcerative colitis.
History of pancreatitis.
Family history of medullary thyroid carcinoma.
Trial design
Treatments tested in this trial
- Beinaglutide
- Insulin aspart
Treatment groups
115 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov